French cosmetic ingredients maker Solabia has acquired the Botanical Actives and In Vitro Diagnostics (IVD) divisions of compatriot Seqens.
The deal comes less than a month after Solabia agreed to acquire Swiss cosmetic ingredient maker Mibelle Biochemistry from Persán of Spain.
Seqens develops and manufactures high performance vegetal active ingredients for cosmetics, as well as plasma and serum solutions for diagnostics applications.
It operates a facility in Limoges, France, which is recognized for its advanced botanical extraction and high-end manufacturing capabilities.
A Solabia spokeswoman said the acquisition represents a strategic opportunity for the Paris-based company to reinforce its global position as a leading supplier of high performance substantiated botanical active ingredients for cosmetics applications, while also securing a critical raw material supply for its diagnostics activities.
Seqens' ingredients and diagnostic solutions are commercialized worldwide and used by leading brands across both sectors, it added.
By combining forces, it said, Solabia will accelerate the development of innovative solutions across both the cosmetics and diagnostics markets, two sectors in which it is already strongly active and committed to long-term growth.
Jean-Baptiste Dellon added: “We are pleased to welcome the Seqens Botanical Actives and IVD teams into Solabia. Because we operate in the same core activities, this acquisition is a natural and highly complementary fit.
“By combining our capabilities, we will reinforce our market position, secure critical supply chains, and offer our clients more robust and innovative solutions. This acquisition fully supports our development strategy as we continue to strengthen our business in markets with strong growth potential.”
Pascal Villemagne, CEO of Seqens, said: “This transaction is fully consistent with our long-term strategic vision. It enables us to further focus on its core priorities, while ensuring that the Limoges teams join a group whose industrial culture, scientific expertise and growth ambitions are strongly aligned with their activities.
“We are confident that this new chapter with Solabia offers a robust and sustainable platform for the continued development of the site, its people and its know-how.”
The financial terms of the deal were not disclosed.
